A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
复制标题
PDGFRB 与 TSC1(mTOR 信号通路内在抑制因子)在患有 t(5;9)(q32;q34) 的慢性嗜酸性粒细胞白血病患者中的新型融合
DOI:
10.1080/10428194.2018.1427855
复制
发表时间:
2018-10
影响因子:
2.6
通讯作者:
中科院分区:
文献类型:
--
作者:
The PDGFRB gene is a frequent target of chromosomal translocation in myeloid/lymphoid neoplasms associated with eosinophilia [1]. The typical abnormal karyotype involved in PDGFRB is a hallmark rearrangement of 5q31-33. So far, more than 30 different PDGFRB fusions have been discovered [2]. The tyrosine kinase inhibitor imatinib is considered definitive treatment for PDGFRB-rearranged neoplasms with eosinophilia, and it has been reported that either imatinib 400 mg/d or imatinib 100 mg/d is sufficient to induce complete remission [3]. Here, we reported the detection of a novel PDGFRB fusion, TSC1-PDGFRB in a patient with eosinophilia, MPN. In addition, we constructed TSC1-PDGFRB and muTSC1-PDGFRB T681I cDNA into MSCV-IRES-GFP, and transduced Ba/F3 cells. Then, the efficiency of TKIs (imatinib, nilotinib) and mTOR inhibitors (torin, rapamycin) were investigated in those Ba/F3 cells transduced by TSC1-PDGFRB or muTSC1-
登录
查看更多内容
影响因子:
3.5
作者:
Jawhar, Mohamad;Naumann, Nicole;Metzgeroth, Georgia
通讯作者:
Metzgeroth, Georgia
影响因子:
9.8
作者:
Feldman ME;Apsel B;Uotila A;Loewith R;Knight ZA;Ruggero D;Shokat KM
通讯作者:
Shokat KM
影响因子:
3.8
作者:
Park S;Sim H;Lee K
通讯作者:
Lee K
影响因子:
56.9
作者:
vanSlegtenhorst, M;deHoogt, R;Kwiatkowski, DJ
通讯作者:
Kwiatkowski, DJ
影响因子:
8
作者:
Wan, X.;Harkavy, B.;Helman, L. J.
通讯作者:
Helman, L. J.